
    
      Random Prospective Study non-blinded with 144 diabetics patients designated to myocardial
      revascularization with cardiopulmonary bypass . 72 patients will be randomly set to usual
      treatment provided by health care service and 72 patients will be randomly assigned treatment
      based on ISGLT2 (Empaglifozin). Patients will receive treatment as set for 3 months until 3
      days prior to surgery. Creatinine levels will be measured immediately after surgery and in
      the following 3 days in post-op.

      To evaluate the possibility to reduce the acute kidney injury in a randomized group treated
      with therapy based on ISGLT2.
    
  